within Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AF03_Zalcitabine;

model Zalcitabine
  extends Pharmacolibrary.Drugs.ATC.J.J05AF03;

  annotation (Documentation(
info       = "<html><body><table><tr><td>name:</td><td>Zalcitabine</td></tr><tr><td>ATC code:</td><td>J05AF03</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Zalcitabine is a nucleoside reverse transcriptase inhibitor (NRTI) formerly used in the treatment of HIV infection. It inhibits viral replication by interfering with reverse transcriptase activity. Due to toxicity concerns and the development of better alternatives, zalcitabine has been withdrawn from the market and is not currently approved for clinical use.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters following oral administration in HIV-infected adult patients; typically studied population included males and females aged 18-60 with normal renal and hepatic function.</p><h4>References</h4><ol><li><p>Adams, JM, et al., &amp; Morse, GD (1998). Zalcitabine population pharmacokinetics: application of radioimmunoassay. <i>Antimicrobial agents and chemotherapy</i> 42(2) 409–413. DOI:<a href=\"https://doi.org/10.1128/AAC.42.2.409\">10.1128/AAC.42.2.409</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/9527795/\">https://pubmed.ncbi.nlm.nih.gov/9527795</a></p></li><li><p>Wen, H, et al., &amp; Zhang, L (2022). Population pharmacokinetics and model-informed precision dosing of lamivudine in Chinese HIV-infected patients with mild and moderate impaired renal function. <i>Expert review of clinical pharmacology</i> 15(5) 647–655. DOI:<a href=\"https://doi.org/10.1080/17512433.2022.2078306\">10.1080/17512433.2022.2078306</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/35938476/\">https://pubmed.ncbi.nlm.nih.gov/35938476</a></p></li><li><p>Kasirye, P, et al., &amp; Walker, AS (2012). Pharmacokinetics of antiretroviral drug varies with formulation in the target population of children with HIV-1. <i>Clinical pharmacology and therapeutics</i> 91(2) 272–280. DOI:<a href=\"https://doi.org/10.1038/clpt.2011.225\">10.1038/clpt.2011.225</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/22190066/\">https://pubmed.ncbi.nlm.nih.gov/22190066</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial generated model</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Zalcitabine;
